Yutrepia, prescribed to over 900 PAH or PH-ILD patients since its May U.S. approval, increased walking distances by over 100 ...

Columnist Jolie Lizana is not just happy to take a day of rest for National Relaxation Day; she contends that such rest is ...

Immune cell metabolism changes may underlie PAH inflammation, which could inform targets for new PAH treatment strategies.

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in ...

People with portopulmonary hypertension (PoPH) show lower survival rates than other PAH types, but targeted PAH treatments ...

A 5-year-old boy with a neuroblastoma developed PAH after receiving a high dose of chemotherapy to prepare for a stem cell ...

To reduce fatigue, the first thing columnist Jen Cueva did was analyze her sleep patterns, revealing some surprising results.

A 5-year-old boy with a neuroblastoma developed PAH after receiving a high dose of chemotherapy to prepare for a stem cell transplant.

A heart ultrasound measure called tricuspid regurgitation could show risk, especially in those considered low risk, based on other measures.

“First-time symptoms of the disease always sounded the same: seemingly vibrant, healthy individuals experiencing shortness of breath, and later at risk of death from pulmonary hypertension. Such was ...

Early treatment with iNO and pulmonary surfactant reduces the risk of developing BPD associated with PH in preterm infants, a study found.